Welcome to Episode Ten of Diabetes By the Numbers.
Today we have our first returning guest. It’s Molly McElwee Malloy, Head of Patient Engagement at TypeZero Technologies in Charlottesville, Virginia. TypeZero is in the news this week for two big undertakings.
First, there’s a 12.7 million dollar artificial pancreas study funded by the National Institutes of Health. It will begin very soon. In this study, they’ll be testing TypeZero’s inControl platform, using a spiffy new device:
Cool, right? This study will include as many as 240 participants! The studies will take place in nine locations… six in the USA, and three in Europe. To find out more about participating in this important research, scroll to the bottom of this post.
The second big piece of news is this: Type Zero is entering into a partnership with CellNovo, which makes an integrated diabetes management system in Europe. They’ve gotten a lot of good press here in the USA, and we talk about that and what this partnership means for TypeZero. Have a listen:
Reference Material – Click below for more information on this topic
Find out more about the inControl diabetes management platform by going to the Type Zero Technologies website:
Clinical trial participants are necessary and appreciated! Though the study will take place in several locations, the overall management of the trial will be handled through the Jaeb Center for Health Research. To contact the Jaeb Center to volunteer to participate, Send an e-mail to:
To find out more about artificial pancreas testing through the University of Virginia’s Center for Diabetes Technology, send an e-mail to:
CellNovo makes a diabetes management system that includes a patch pump, an activity monitor, a hand held cell-enabled handset, and a continuous glucose monitor. Data can be shared via the cloud. To learn more about CellNovo, go to:
Follow Molly McElwee Malloy on Twitter: